Access Industries updates 6.02% Yarrow Bioscience stake (NASDAQ: VYNE)
Rhea-AI Filing Summary
Yarrow Bioscience, Inc. received an Amendment No. 1 to a Schedule 13D from AI Biotechnology LLC, Access Industries Holdings LLC, Access Industries Management, LLC and Len Blavatnik, updating their beneficial ownership following a merger and 1-for-50 reverse stock split.
The reporting group now reports beneficial ownership of 178,180 shares of common stock, consisting of 22,331 shares held directly by AI Biotechnology and 155,849 shares issuable upon exercise of pre-funded warrants, representing 6.02% of Yarrow's common stock. The percentage is based on 2,803,078 shares outstanding after the merger plus the warrant shares. Before the reverse split, AI Biotechnology held 1,116,585 shares and warrants for 7,792,448 shares, which were proportionately adjusted. Upstream Access entities and Mr. Blavatnik may be deemed to share voting and dispositive power over these securities but disclaim beneficial ownership, and they report no other transactions in the past 60 days beyond those described.
Positive
- None.
Negative
- None.
Key Figures
Beneficial ownership: 178,180 shares
Ownership percentage: 6.02%
Direct common shares: 22,331 shares
+5 more
8 metrics
Beneficial ownership
178,180 shares
Total common stock and warrant shares reported as beneficially owned
Ownership percentage
6.02%
Portion of Yarrow Bioscience common stock class beneficially owned
Direct common shares
22,331 shares
Common stock held directly by AI Biotechnology LLC after reverse split
Shares underlying warrants
155,849 shares
Common stock issuable upon exercise of pre-funded warrants
Shares outstanding
2,803,078 shares
Common stock issued and outstanding after merger and reverse split
Reverse split ratio
1-for-50
Each 50 shares of common stock combined into one share
Pre-split holdings
1,116,585 shares
AI Biotechnology common shares before the 1-for-50 reverse split
Pre-split warrant shares
7,792,448 shares
Common shares previously issuable upon warrant exercise before adjustment
Key Terms
Schedule 13D, reverse stock split, pre-funded warrants, beneficial ownership, +1 more
5 terms
Schedule 13D regulatory
"Amendment No. 1 to a Schedule 13D from AI Biotechnology LLC"
A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.
reverse stock split financial
"the Issuer effected a 1-for-50 reverse stock split of its Common Stock"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
pre-funded warrants financial
"shares of Common Stock issuable upon the exercise of pre-funded warrants"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
beneficial ownership financial
"The percent of Common Stock reported as beneficially owned is calculated"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Agreement and Plan of Merger and Reorganization regulatory
"pursuant to the Agreement and Plan of Merger and Reorganization, dated as of December 17, 2025"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What ownership stake in VYNE does the Schedule 13D/A report?
The amendment reports beneficial ownership of 178,180 shares of Yarrow Bioscience common stock, representing 6.02% of the outstanding class. This includes 22,331 shares held directly and 155,849 shares issuable upon exercise of pre-funded warrants.
What corporate actions involving VYNE triggered this Schedule 13D/A amendment?
The amendment reflects a merger where Yellow Merger Sub Corp. combined with Pre-Merger Yarrow and VYNE Therapeutics Inc. was renamed Yarrow Bioscience, Inc.. It also reflects a 1-for-50 reverse stock split of the common stock completed shortly before the merger.
How was the 6.02% beneficial ownership in VYNE calculated?
The 6.02% figure uses as its base 2,803,078 shares of common stock outstanding after the merger and reverse split, plus 155,849 shares of common stock issuable upon exercise of pre-funded warrants held by AI Biotechnology LLC.
Do Access Industries and Len Blavatnik fully own the reported VYNE securities?
The amendment states the securities are owned directly by AI Biotechnology LLC. Access Industries entities and Len Blavatnik may be deemed to share voting and dispositive power through control relationships but expressly disclaim beneficial ownership of these securities.